1383816-29-2 Usage
Description
Tropifexor is a potent non-bile acid farnesoid X receptor (FXR) agonist, which is a type of nuclear receptor that plays a crucial role in regulating bile acid homeostasis, lipid metabolism, and inflammation. It is primarily used for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH).
Uses
Used in Pharmaceutical Industry:
Tropifexor is used as a therapeutic agent for the treatment of cholestatic liver diseases, which are conditions characterized by impaired bile flow and accumulation of bile acids in the liver. It helps in reducing bile acid synthesis, promoting bile secretion, and mitigating liver injury.
Tropifexor is also used as a treatment for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD) that can lead to liver inflammation, fibrosis, and potentially liver failure. By targeting the FXR pathway, Tropifexor modulates various metabolic and inflammatory processes, which can help in reducing liver fat, inflammation, and fibrosis associated with NASH.
Check Digit Verification of cas no
The CAS Registry Mumber 1383816-29-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,3,8,1 and 6 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1383816-29:
(9*1)+(8*3)+(7*8)+(6*3)+(5*8)+(4*1)+(3*6)+(2*2)+(1*9)=182
182 % 10 = 2
So 1383816-29-2 is a valid CAS Registry Number.
1383816-29-2Relevant articles and documents
COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES
-
, (2020/12/07)
In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.
COMPOSITIONS AND METHODS FOR MODULATING FXR
-
, (2012/07/13)
The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
